| Literature DB >> 21748365 |
Toru Hirano1, Nobuyuki Ohguro, Satoshi Hohki, Keisuke Hagihara, Yoshihito Shima, Masashi Narazaki, Atsushi Ogata, Kazuyuki Yoshizaki, Atsushi Kumanogoh, Tadamitsu Kishimoto, Toshio Tanaka.
Abstract
A 47-year-old female patient with Behçet's disease had been treated with colchicine, prednisolone, cyclosporine A, and infliximab. Because she relapsed, however, treatment with tocilizumab, a humanized anti-interleukin 6 receptor antibody, was started. This treatment suppressed the patient's clinical manifestations, including ocular attacks, for 1 year and improved her visual acuity. This experience indicates that tocilizumab may constitute a therapeutic option for refractory Behçet's disease.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21748365 DOI： 10.1007/s10165-011-0497-5
Source DB: PubMed Journal: Mod Rheumatol ISSN： 1439-7595 Impact factor: 3.023